A method for screening drugs that reduce the stiffness of gastric cancer tissue and its application

By using a 3D co-culture model of gastric cancer cells and gastric cancer-associated fibroblasts, combined with fluorescence labeling and atomic force microscopy, the problem of the inability to simulate the stiffness of gastric cancer tissue in existing technologies has been solved. This enables efficient screening of drugs that reduce the stiffness of gastric cancer tissue, thereby reducing research and development costs and time.

CN123108102APending Publication Date: 2026-11-17PEKING UNIV CANCER HOSPITAL INNER MONGOLIA HOSPITAL (AFFILIATED CANCER HOSPITAL OF INNER MONGOLIA MEDICAL UNIV INNER MONGOLIA AUTONOMOUS REGION CANCER HOSPITAL INNER MONGOLIA AUTONOMOUS REGION CANCER CENT)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510636512.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-05-17
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies cannot effectively simulate the high hardness of gastric cancer tissue, and there is a lack of efficient drug screening methods to reduce the hardness of gastric cancer tissue, resulting in high research and development costs, long cycles, and difficulty in large-scale screening of effective drugs.

Method used

A 3D co-culture model of gastric cancer cells and gastric cancer-associated fibroblasts was used to simulate the stiffness of gastric cancer tissue by forming 3D cell spheres. Gastric cancer cells were labeled with green fluorescent protein, and drugs that reduce the stiffness of gastric cancer tissue were screened by combining atomic force microscopy and a fully automated cell counter.

Benefits of technology

This method enables efficient simulation of gastric cancer tissue stiffness in vitro, and allows for rapid and accurate screening of drugs that can reduce the stiffness of gastric cancer tissue through drug screening methods, thereby reducing research and development costs and time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123108102A_ABST
    Figure CN123108102A_ABST
Patent Text Reader

Abstract

This invention discloses a method for screening drugs that reduce the stiffness of gastric cancer tissue. In this method, gastric cancer cells and gastric cancer-associated fibroblasts are co-cultured in a 3D hanging drop method. The resulting 3D cell spheres exhibit significantly higher stiffness than those formed by co-culturing gastric cancer cells and normal gastric fibroblasts, effectively mimicking the high stiffness characteristic of gastric cancer tissue. During drug screening, the test drug can be added directly to the co-culture hanging drop, or the gastric cancer-associated fibroblasts can be pretreated with the test drug before co-culturing. After co-culturing, cell spheres from the control group and the drug group are collected separately. The stiffness, size, number of gastric cancer cells in the cell spheres, and activation level of stiffness-related signaling pathways in the gastric cancer cells are measured to evaluate the drug's effect on reducing the stiffness of gastric cancer tissue.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical technology, specifically to a method for screening drugs that reduce the hardness of gastric cancer tissue and its application. Background Technology

[0002] Stomach cancer is a serious disease that threatens human health and life, with more than 900,000 new cases and over 780,000 deaths worldwide each year. The clinical manifestations of stomach cancer are diverse, and early symptoms are often subtle. Many patients are diagnosed at an advanced stage, resulting in poor prognosis and low survival rates. There is an urgent need to develop new treatment strategies and effective drugs to alleviate the suffering of patients.

[0003] Gastric cancer tissue contains not only gastric cancer cells but also various cell types, including gastric cancer-associated fibroblasts, macrophages, infiltrating immune cells, and vascular endothelial cells, which together constitute the gastric cancer microenvironment. This microenvironment provides favorable conditions and strong support for the survival and evolution of gastric cancer cells. Past research on the gastric cancer microenvironment has largely focused on its role in promoting malignant behavior of gastric cancer cells through various chemical signals. Recent studies have revealed that, compared to normal tissue, the gastric cancer microenvironment possesses high biophysical stiffness. This high stiffness can act on mechanosensing signaling molecules on the surface of gastric cancer cells, activating mechanosensing pathways within the cells and promoting malignant behaviors such as proliferation, metastasis, and immune escape. Therefore, reducing the stiffness of gastric cancer tissue holds promise as an effective way to inhibit gastric cancer progression.

[0004] The interaction between gastric cancer cells and gastric cancer-associated fibroblasts is a key reason for the high rigidity of gastric cancer tissue. Gastric cancer cells act on gastric cancer-associated fibroblasts by secreting various soluble factors and exosomes, prompting these fibroblasts to synthesize and release large amounts of collagen fibers and collagen-modifying enzymes. As a result, on the one hand, a large amount of collagen fibers are deposited in the limited intratumoral space, placing the tumor's biomolecules and cells in a highly compressed state, increasing the rigidity of the tumor tissue. On the other hand, the large amount of collagen-modifying enzymes increases the cross-linking between collagen fibers, causing the deposited collagen fibers to form a dense lamellar structure. This dense lamellar structure is stacked together and lacks deformation capacity, keeping the tumor tissue in a rigid state, further increasing its rigidity.

[0005] To conduct in-depth research on the stiffness of gastric cancer tissue and explore effective interventions, it is necessary to comprehensively consider the complex interactions between gastric cancer cells and gastric cancer-related fibroblasts. Two-dimensional cultured gastric cancer cell lines cannot simulate this property of tumors, nor can they effectively screen for corresponding intervention drugs. Using mouse xenograft models for related research is costly, time-consuming, complex, and difficult to perform, hindering large-scale, high-throughput drug studies. Therefore, there is an urgent need to establish an in vitro culture system capable of simulating the stiffness of gastric cancer tissue, and an efficient and accurate drug screening method based on this system, to accelerate the development of drugs that can effectively reduce the stiffness of gastric cancer tissue. Summary of the Invention

[0006] To address the aforementioned needs, this invention discloses a drug screening method based on a 3D co-culture model of gastric cancer cells and gastric cancer-associated fibroblasts. This method can solve the problem of the inability to screen drugs that reduce the stiffness of gastric cancer tissue on a large scale.

[0007] In the method disclosed in this invention, gastric cancer cells and gastric cancer-related fibroblasts are first co-cultured in 3D using a hanging drop method. The 3D cell spheres formed by this co-culture exhibit significantly higher rigidity than those formed by co-culturing gastric cancer cells and normal gastric fibroblasts, thus effectively mimicking the high rigidity characteristic of gastric cancer tissue. Furthermore, the co-cultured gastric cancer cells are pre-labeled with green fluorescent protein, allowing for convenient counting and sorting of the cancer cells within the cell spheres after culture, and enabling the detection of the activation level of rigidity-related signaling pathways.

[0008] When screening drugs, the test drug can be added directly to the co-culture droplet, or the gastric cancer-related fibroblasts can be pretreated with the test drug before co-culturing. After the culture is completed, cell spheres from the control group and the drug group are collected respectively. The stiffness of the cell spheres, the size of the cell spheres, the number of gastric cancer cells in the cell spheres, and the degree of activation of stiffness-related signaling pathways in gastric cancer cells can be detected. This allows for a preliminary evaluation of the drug's effect on reducing the stiffness of gastric cancer tissue. Attached Figure Description

[0009] Figure 1 Spheroids formed by co-culturing gastric cancer cells with normal gastric fibroblasts and gastric cancer cells with gastric cancer-associated fibroblasts.

[0010] Figure 2 Results of atomic force microscopy measurements on the hardness of spheroids. GNF: Normal gastric fibroblasts; GCAF: Gastric cancer-associated fibroblasts. *** P <0.001 vs. HGC-27 and GNF co-culture group.

[0011] Figure 3Pretreatment with 3,29-dibenzoyltrichosanthes glycol reduced the stiffness of 3D spheroids in gastric cancer cells—specifically, gastric cancer-associated fibroblasts. *** P <0.001 vs. DMSO pretreatment group Figure 4 Pretreatment with 3,29-dibenzoyltrichosanthes glycol inhibited the growth of spheroids.

[0012] Figure 5 Pretreatment with 3,29-dibenzoyltrichosanthes glycol inhibited the proliferation of gastric cancer cells in spheroidoids. *** P <0.001 vs. DMSO pretreatment group. Detailed Implementation

[0013] To make the objectives and advantages of the present invention clearer, the present invention will be further described in detail below with reference to embodiments. It should be understood that the specific embodiments described herein are only for explaining the present invention and are not intended to limit the present invention.

[0014] Example 1: Establishment of a 3D co-culture system of gastric cancer cells and gastric cancer-associated fibroblasts using the hanging drop method. HGC-27 gastric cancer cell line was passaged and stably transfected with the green fluorescent protein gene using a lentiviral vector to obtain HGC-27-EGFP cells. Primary cultures of normal gastric fibroblasts and gastric cancer-associated fibroblasts were also conducted. Cell suspensions of the three cell types in logarithmic growth phase were prepared and counted. HGC-27-EGFP cells were then mixed with normal gastric fibroblasts and gastric cancer-associated fibroblasts (mixing ratio: cancer cells / fibroblasts = 4:1). 20 µL of the mixed cell suspension was prepared as a droplet and placed on the lid of a 10 cm culture dish. The lid was then gently placed on the bottom of the dish, and 10 mL of PBS was added to the bottom to maintain humidity. The dish was then gently placed in a 37°C, 5% CO2 incubator. After 12 days of culture, the formation of 3D spheroids and their growth were observed under a microscope.

[0015] The results showed that both co-culture of gastric cancer cells and normal gastric fibroblasts and co-culture of gastric cancer cells and gastric cancer-associated fibroblasts could form 3D spheroids, with the latter spheroids growing significantly faster than the former (Figure 1).

[0016] Example 2: Detection of the hardness of spheroids formed by co-culture of gastric cancer cells and gastric cancer-associated fibroblasts Spheroids formed from co-cultures of gastric cancer cells and normal gastric fibroblasts, and co-cultures of gastric cancer cells and gastric cancer-associated fibroblasts, were collected separately. Individual spheroids were placed on the stage of an atomic force microscope using a fine pipette, and their Young's modulus was measured using the microscope. The magnitude of the Young's modulus was used to characterize the hardness of the spheroids.

[0017] The results showed that the hardness of the spheroids formed by co-culturing gastric cancer cells and gastric cancer-associated fibroblasts was significantly higher than that of the spheroids formed by co-culturing gastric cancer cells and normal gastric fibroblasts, which better simulated the high hardness characteristics of gastric cancer tissue (Figure 2).

[0018] Example 3: Screening for drugs that reduce the hardness of 3D spheroids of gastric cancer cells-gastric cancer-associated fibroblasts. Gastric cancer-associated fibroblasts were pretreated with compounds from the research group's self-built compound library for 72 h, and then co-cultured with gastric cancer cells. The hardness of the spheroids was detected by atomic force microscopy, the growth of the spheroids was observed under a microscope, and the proliferation capacity of gastric cancer cells in the spheroids was detected by an automated cell counter.

[0019] The results showed that 3,29-dibenzoyltrichosanthes diol significantly reduced the stiffness of 3D spheroids of gastric cancer cells-gastric cancer-associated fibroblasts (Figure 3), inhibited the growth of spheroids (Figure 4), and suppressed the proliferation of gastric cancer cells in spheroids (Figure 5).

[0020] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A method for screening drugs for reducing the hardness of gastric cancer tissue, characterized in that: gastric cancer cells are labeled with green fluorescent protein, and then the gastric cancer cells are co-cultured with gastric cancer-associated fibroblasts by the hanging drop method to obtain 3D cell spheres with high hardness; in the drug screening, the drugs to be tested are directly added in the hanging drops or the gastric cancer-associated fibroblasts are pretreated with the drugs to be tested before co-culturing.

2. The method for screening drugs to reduce the hardness of gastric cancer tissue according to claim 1, characterized in that, After the 3D co-culturing, the means for evaluating the effect of the drugs include: atomic force microscopy is used to detect the Young's modulus of the 3D cell spheres, an inverted phase contrast microscope is used to observe the growth of the 3D cell spheres, and a full-automatic cell counter is used to detect the number of gastric cancer cells in the 3D cell spheres. 3.The method for screening drugs for reducing the hardness of gastric cancer tissue according to claims 1-2, which is used in screening anti-tumor drug targets and preparing anti-tumor drugs.